Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.

biliary tract cancer cholangiocarcinoma circulating tumor DNA (ctDNA) gallbladder cancer ivosidenib molecular profiling next-generation sequencing pemigatinib targeted therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
24 Jul 2020
Historique:
received: 30 06 2020
revised: 21 07 2020
accepted: 23 07 2020
entrez: 30 7 2020
pubmed: 30 7 2020
medline: 30 7 2020
Statut: epublish

Résumé

Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree. BTCs are characterized by presentation with advanced disease precluding curative surgery, rising global incidence, and a poor prognosis. Chemotherapy is the mainstay of the current treatment, which results in a median overall survival of less than one year, underscoring the need for novel therapeutic agents and strategies. Next-generation sequencing-based molecular profiling has shed light on the underpinnings of the complex pathophysiology of BTC and has uncovered numerous actionable targets, leading to the discovery of new therapies tailored to the molecular targets. Therapies targeting fibroblast growth factor receptor (FGFR) fusion, isocitrate dehydrogenase (IDH) mutations, the human epidermal growth factor receptor (HER) family, DNA damage repair (DDR) pathways, and

Identifiants

pubmed: 32722188
pii: cancers12082039
doi: 10.3390/cancers12082039
pmc: PMC7465131
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Chin Clin Oncol. 2020 Feb;9(1):2
pubmed: 32008328
Ann Oncol. 2015 Mar;26(3):542-7
pubmed: 25538178
Lancet Oncol. 2012 Feb;13(2):181-8
pubmed: 22192731
Lancet Oncol. 2020 Aug 17;:
pubmed: 32818466
Clin Cancer Res. 2006 Jun 15;12(12):3657-60
pubmed: 16778093
Am J Physiol Renal Physiol. 2007 Nov;293(5):F1577-83
pubmed: 17699549
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nat Genet. 2013 Dec;45(12):1474-8
pubmed: 24185513
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Br J Cancer. 2018 Aug;119(3):291-295
pubmed: 29955136
Lancet Oncol. 2020 Jan;21(1):e29-e41
pubmed: 31908303
Clin Gastroenterol Hepatol. 2013 Jan;11(1):13-21.e1; quiz e3-4
pubmed: 22982100
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
J Gastrointest Oncol. 2016 Aug;7(4):556-61
pubmed: 27563445
BMC Cancer. 2016 Feb 24;16:153
pubmed: 26912134
Cancer Discov. 2016 Jul;6(7):727-39
pubmed: 27231123
JAMA Oncol. 2019 Jun 1;5(6):824-830
pubmed: 30998813
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
J Clin Oncol. 2011 Jun 10;29(17):2357-63
pubmed: 21519026
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
BMC Cancer. 2019 Jan 11;19(1):55
pubmed: 30634942
Lancet Oncol. 2015 Aug;16(8):967-78
pubmed: 26179201
Br J Cancer. 2020 Mar;122(5):634-639
pubmed: 31919404
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
PLoS One. 2011 Jan 06;6(1):e15640
pubmed: 21253578
Oncology. 2012;82(3):175-9
pubmed: 22433475
Int J Cancer. 2020 Jun 11;:
pubmed: 32525595
Clin Chim Acta. 2016 Jul 1;458:138-43
pubmed: 27181912
Int J Cancer. 2020 Jul 23;:
pubmed: 32700810
Nat Genet. 2012 May 06;44(6):690-3
pubmed: 22561520
Eur J Cancer. 2017 Dec;87:122-130
pubmed: 29145038
Sci Rep. 2019 Apr 3;9(1):5548
pubmed: 30944390
Oncologist. 2018 Dec;23(12):1407-e136
pubmed: 29853658
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Nat Rev Clin Oncol. 2020 Jul 6;:
pubmed: 32632268
Ann Oncol. 2016 Apr;27(4):599-608
pubmed: 27005468
Br J Cancer. 2017 Feb 28;116(5):561-567
pubmed: 28081540
Oncology. 1999 Apr;56(3):177-80
pubmed: 10202270
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Oncotarget. 2017 Feb 28;8(9):15014-15022
pubmed: 28122360
Ann Oncol. 2010 Oct;21 Suppl 7:vii345-8
pubmed: 20943640
Oncologist. 2020 May;25(5):380-e763
pubmed: 31826977
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
Invest New Drugs. 2012 Apr;30(2):708-13
pubmed: 20924641
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
BMC Cancer. 2011 Feb 08;11:60
pubmed: 21303542
Sci Rep. 2019 Sep 13;9(1):13261
pubmed: 31519967
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Ann Oncol. 2014 Jul;25(7):1416-1421
pubmed: 24737778
Oncol Rep. 2014 Aug;32(2):700-8
pubmed: 24927194
BMC Cancer. 2020 Apr 15;20(1):318
pubmed: 32293336
Int J Mol Sci. 2019 Jan 24;20(3):
pubmed: 30682771
Lancet Oncol. 2014 Jul;15(8):819-28
pubmed: 24852116
Curr Gastroenterol Rep. 2011 Apr;13(2):182-7
pubmed: 21271364
J Gastrointest Oncol. 2019 Aug;10(4):751-765
pubmed: 31392056
Br J Cancer. 2018 Apr;118(7):966-971
pubmed: 29527009
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
J Surg Res. 2013 Sep;184(1):304-11
pubmed: 23866788
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Cancer. 2016 Feb 15;122(4):574-81
pubmed: 26540314
Cancer. 2016 Dec 15;122(24):3838-3847
pubmed: 27622582
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Ann Oncol. 2014 Dec;25(12):2328-38
pubmed: 24769639
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
Oncotarget. 2017 Feb 28;8(9):14957-14968
pubmed: 28146430
Br J Cancer. 2018 Feb 20;118(4):462-470
pubmed: 29348486
Br J Cancer. 2010 Jan 5;102(1):68-72
pubmed: 19935794
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
Cancer. 2019 Mar 15;125(6):902-909
pubmed: 30561756
J Huazhong Univ Sci Technolog Med Sci. 2017 Apr;37(2):172-178
pubmed: 28397047
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720
pubmed: 31300360
Hepatobiliary Surg Nutr. 2020 Aug;9(4):414-424
pubmed: 32832493
PLoS One. 2014 Dec 23;9(12):e115383
pubmed: 25536104
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
Cancer. 2017 Jun 1;123(11):1979-1988
pubmed: 28192597

Auteurs

Sakti Chakrabarti (S)

Department of Hematology-Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.

Mandana Kamgar (M)

Department of Hematology-Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.

Amit Mahipal (A)

Department of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Classifications MeSH